business

Leerink reiterates Edgewise Therapeutics stock rating on trial data

Investing.com · Jun 16, 2026, 1:43 PM · Also reported by 2 other sources

Read full story on Investing.com → More top stories

Also covered by

Yahoo Finance Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now? Yahoo Finance Why This AI Data Center Stock Is Surging 21% on an AMD Partnership

Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Leerink reiterates Edgewise Therapeutics stock rating on trial data

Also covered by

More in business